Identification of flavonoid-based small molecule inhibitors with dual-targeting capability against RdRp and Mpro of SARS-CoV-2
- 8 December 2025
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130501
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences
This publication has 31 references indexed in Scilit:
- Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon systemAntiviral Research, 2024
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infectionsNature Communications, 2024
- Emerging SARS-CoV-2 Resistance After Antiviral TreatmentJAMA Network Open, 2024
- Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2Med, 2023
- Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2Antiviral Research, 2022
- Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19Computers in Biology and Medicine, 2022
- The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic targetCell Death & Differentiation, 2021
- Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2Journal of Virological Methods, 2021
- Structural Basis for RNA Replication by the SARS-CoV-2 PolymeraseCell, 2020
- Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sitesAntiviral Research, 2020